Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Muscle Activation in Traditional and Experimental Barbell Bench Press Exercise: A Potential New Tool for Fitness Maintenance.

Melani A, Gobbi G, Galli D, Carubbi C, Masselli E, Neri LM, Giovinco G, Cicchella A, Galuppo L, Presta V, Vaccarezza M, Vitale M, Mirandola P.

Sports (Basel). 2019 Oct 17;7(10). pii: E224. doi: 10.3390/sports7100224.

2.

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib.

Marisi G, Petracci E, Raimondi F, Faloppi L, Foschi FG, Lauletta G, Iavarone M, Canale M, Valgiusti M, Neri LM, Ulivi P, Orsi G, Rovesti G, Vukotic R, Conti F, Cucchetti A, Ercolani G, Andrikou K, Cascinu S, Scartozzi M, Casadei-Gardini A.

Cancers (Basel). 2019 Jul 20;11(7). pii: E1023. doi: 10.3390/cancers11071023.

3.

Rediscovering Medicinal Amazonian Aromatic Plants: Piper carpunya (Piperaceae) Essential Oil as Paradigmatic Study.

Ballesteros JL, Tacchini M, Spagnoletti A, Grandini A, Paganetto G, Neri LM, Marengo A, Angiolella L, Guerrini A, Sacchetti G.

Evid Based Complement Alternat Med. 2019 Jan 1;2019:6194640. doi: 10.1155/2019/6194640. eCollection 2019.

4.

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab.

Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P.

Cancer Manag Res. 2018 Nov 14;10:5659-5666. doi: 10.2147/CMAR.S181570. eCollection 2018.

5.

miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model.

Callegari E, D'Abundo L, Guerriero P, Simioni C, Elamin BK, Russo M, Cani A, Bassi C, Zagatti B, Giacomelli L, Blandamura S, Moshiri F, Ultimo S, Frassoldati A, Altavilla G, Gramantieri L, Neri LM, Sabbioni S, Negrini M.

Mol Ther Nucleic Acids. 2018 Jun 1;11:485-493. doi: 10.1016/j.omtn.2018.04.002. Epub 2018 Apr 12.

6.

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.

Marisi G, Scarpi E, Passardi A, Nanni O, Ragazzini A, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P.

Sci Rep. 2017 May 2;7(1):1293. doi: 10.1038/s41598-017-01420-0.

7.

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.

Lonetti A, Cappellini A, Bertaina A, Locatelli F, Pession A, Buontempo F, Evangelisti C, Evangelisti C, Orsini E, Zambonin L, Neri LM, Martelli AM, Chiarini F.

J Hematol Oncol. 2016 Oct 24;9(1):114.

8.

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.

Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M, Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Della Corte C, Neri LM, Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti E, Ulivi P, Frassineti GL.

Oncotarget. 2016 May 10;7(19):27988-99. doi: 10.18632/oncotarget.8569.

9.

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.

Buontempo F, Orsini E, Lonetti A, Cappellini A, Chiarini F, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, Bertacchini J, Neri LM, McCubrey JA, Martelli AM.

Oncotarget. 2016 Jan 12;7(2):1323-40. doi: 10.18632/oncotarget.6361.

10.

The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells.

Schult C, Dahlhaus M, Ruck S, Sawitzky M, Amoroso F, Lange S, Etro D, Glass A, Fuellen G, Boldt S, Wolkenhauer O, Neri LM, Freund M, Junghanss C.

BMC Cancer. 2010 Oct 15;10:560. doi: 10.1186/1471-2407-10-560.

11.

Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cells.

Missiroli S, Etro D, Buontempo F, Ye K, Capitani S, Neri LM.

Int J Biochem Cell Biol. 2009 Mar;41(3):570-7. doi: 10.1016/j.biocel.2008.07.002. Epub 2008 Jul 18.

PMID:
18694847
12.

Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines.

Falco GD, Neri LM, Falco MD, Bellan C, Yu Z, Luca AD, Leoncini L, Giordano A.

Oncogene. 2002 Oct 24;21(49):7464-70.

Supplemental Content

Loading ...
Support Center